Galectin Binding to Neo-Glycoproteins: LacDiNAc Conjugated BSA as Ligand for Human Galectin-3

• Published in: Biomolecules (Basel, Switzerland) Vol. 5; no. 3; pp. 1671 - 1696
• Main Authors: Böcker, Sophia, Laaf, Dominic, Elling, Lothar
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.07.2015; MDPI
• Subjects: Animals; Carbohydrate Conformation; Cattle; chemo-enzymatic synthesis; Galectin 1 - metabolism; Galectin 3 - metabolism; galectin-3; Glycoproteins - chemical synthesis; Glycoproteins - chemistry; Glycoproteins - metabolism; Glycoproteins - pharmacology; Humans; LacDiNAc; Lactose - analogs & derivatives; Lactose - chemistry; Lactose - metabolism; Ligands; Models, Molecular; multivalency; neo-glycoproteins; Protein Binding - drug effects; Serum Albumin, Bovine - metabolism; LacDiNAc; chemo-enzymatic synthesis; galectin-3; multivalency; neo-glycoproteins
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom5031671

Carbohydrate-lectin interactions are relatively weak. As they play an important role in biological recognition processes, multivalent glycan ligands are designed to enhance binding affinity and inhibitory potency. We here report on novel neo-glycoproteins based on bovine serum albumin as scaffold for multivalent presentation of ligands for galectins. We prepared two kinds of tetrasaccharides (N-acetyllactosamine and N,N-diacetyllactosamine terminated) by multi-step chemo-enzymatic synthesis utilizing recombinant glycosyltransferases. Subsequent conjugation of these glycans to lysine groups of bovine serum albumin via squaric acid diethyl ester yielded a set of 22 different neo-glycoproteins with tuned ligand density. The neo-glycoproteins were analyzed by biochemical and chromatographic methods proving various modification degrees. The neo-glycoproteins were used for binding and inhibition studies with human galectin-3 showing high affinity. Binding strength and inhibition potency are closely related to modification density and show binding enhancement by multivalent ligand presentation. At galectin-3 concentrations comparable to serum levels of cancer patients, we detect the highest avidities. Selectivity of N,N-diacetyllactosamine terminated structures towards galectin-3 in comparison to galectin-1 is demonstrated. Moreover, we also see strong inhibitory potency of our scaffolds towards galectin-3 binding. These novel neo-glycoproteins may therefore serve as selective and strong galectin-3 ligands in cancer related biomedical research.